Clover Biopharmaceuticals partners up with GSK to accelerate coronavirus vaccine development

pharmafile | February 24, 2020 | News story | Sales and Marketing China, Clover Biopharmaceuticals, GSK, coronavirus, pharma 

Chinese biotech firm Clover Biopharmaceuticals has joined the race to develop interventions against the ongoing coronavirus outbreak with the announcement that it has partnered up with GlaxoSmithKline (GSK) to aid in development of its protein-based “COVID-19 S-Trimer” vaccine.

As part of the newly announced partnership, Clover will leverage GSK’s pandemic adjuvant system to further improve the vaccine’s immunogenicity – its ability to provoke a response from the body’s immune system – in preclinical studies.

“At Clover we look forward to evaluating the combination of GSK’s pandemic adjuvant system and our S-Trimer as a vaccine candidate. Utilizing our proprietary Timer-Tag technology that has been shown to be recognised by antibodies produced by multiple previously-infected coronavirus patients, S-Trimer is being rapidly developed to support global efforts in combating this current and any future coronavirus outbreaks,” explained Joshua Liang, Chief Strategy Officer and Board Director at Clover.

The hope of the collaboration is that development of the vaccine can be considerably accelerated, with the hope that Clover can then quickly up-scale its production to generate large quantities of the vaccine by utilising its in-house cGMP biomanufacturing function – one of the largest of its kind in the country.

“We are proud to contribute to cutting edge research from scientists at Clover Biopharmaceuticals in China as part of our strategy to make our adjuvant technology available to selected partners who have a promising vaccine candidate against the newly emerged coronavirus,” commented Thomas Breuer, Chief Medical Officer of GSK Vaccines. “The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.”

Matt Fellows

Related Content

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …

GSK and Save the Children extend partnership for unvaccinated children

GSK and Save the Children have announced that they will be renewing their partnership for …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

Latest content